336 Quotes by Barry Hyman

I think the movement we've seen since the beginning of the year, with a few weeks up, a few weeks down, is likely to continue at least through the end of the quarter.

This is just a continued consolidation in the industry on a global basis, ... You're seeing Credit Suisse take a bigger stake in the research end of things -- it's good for Credit Suisse because it gives them better asset management and greater size.

This is clearly a number on wage inflation that the market did not want to see. It's clearly disturbing to see wages at this level and I think it's going to weigh on the market for some time.

I think the picture is optimistic and earnings in general have been better than expected.

I want to see more comments from the CEO saying things are stabilizing, ... The market has its test coming in the next four-to-six weeks.

I think that puts a little bit of pressure on the market.

I think, ... that Pfizer is going to benefit from their merger with Warner-Lambert. I think that makes a very good deal. But most pharmaceutical companies do eventually strike deals with biotech companies in terms of marketing their product. And the genomic companies don't have a lot of cash. They have a lot of high valuations, but they don't have a lot of dollars to spend. So, they usually look toward the pharmaceutical sector to help them out, which usually helps both sectors.

At the same time, there is this increased market volatility that exaggerates these swings.

The intermediate background look in terms of interest rates peaking and the economy slowing to a more sustainable pace without any undue harm is slowly going to play itself out. I would be very shocked if the GDP came in anywhere higher than estimates because Wall Street is already expressing its confidence that the economy is slowing down.